Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice
In support of this mechanism, the experimental drugs GTX-102 ( ION582 ( and RO7248824 ( utilize NAT-targeting ASOs and are currently undergoing phase 1/2 clinical trials in pediatric and adult AS patients
Cysteine can be easily oxidized to form a dimer containing disulfide bridge between two cysteines
Ethical approval No research involving humans and/or animals was carried out
In a subject already harboring an occult malignancy, chronically supplying a pro-migratory, pro-angiogenic signal is a theoretically unfavorable intervention, and no long-term animal study has been conducted to exclude that risk